Molecular Biology Program

The John Petrini Lab


Pictured: John Petrini
John Petrini, PhD
Chair, Molecular Biology Program, SKI; Director, The Functional Genomics Initiative

Work in our laboratory is focused on understanding the molecular transactions that govern chromosome stability and replication. The association of cancer predisposition and other pathology with mutations that affect chromosomal metabolism forms the basis of our interest in this process. In this regard, we focus on a conserved multiprotein complex that includes Mre11, Rad50, and Nbs1 in mammals or Xrs2 in the budding yeast S. cerevisiae. Our laboratory has isolated and characterized the human Mre11 complex, hMre11, hRad50, and Nbs1. We proved that an analogue of the S. cerevisiae Mre11 complex exists in human cells, and subsequently established definitive evidence that the yeast and human complexes mediate double-strand break repair in S. cerevisiae and mammalian cells, respectively. Our data suggest that in human cells, the complex acts as a sensor of DNA damage that participates in the activation of cell cycle checkpoints following g-irradiation.

View Lab Overview


Kim, JH., Penson, A.V., Taylor,B.S., Petrini, J.H., (2019) Nbn-Mre11 interaction is required for tumor suppression and genomic integrity. 2019:201905305. doi: 10.1073/pnas. 1905305116. Proc Natl Acad Sci. PMC6660787

Kim, JH., Grosbart, M., Anand, R., Wyman C., Cejka, P., Petrini, J.H., (2017) The Mre11-Nbs1 interface is essential for viability and tumor suppression. Cell Rep. 18. (2) 496-507 PMC5234850

View All Publications


Pictured: John Petrini

John Petrini, PhD

Chair, Molecular Biology Program, SKI; Director, The Functional Genomics Initiative

  • Molecular biologist John Petrini investigates the repair of chromosomal breaks and the activation of the DNA-damage-induced cell-cycle checkpoints.
  • PhD, University of Michigan Medical School
[email protected]
Email Address
Office Phone
Download CV
PDF File


Pictured: John Petrini
John Petrini

Lab Head

Tarsha Barton
Tarsha Barton

Lead Administrative Assistant & Internal Competition Coordinator (FGI)

Fiorella Ghisays, PhD
Fiorella Ghisays

Research Fellow

Marcel Hohl, Research Fellow
Marcel Hohl

Research Fellow

Jun Hyun Kim

Research Fellow

Claudia Canasto, Research Tech/Lab Manager
Claudia Canasto

Research Tech/Lab Manager

Laura Fenney, Research Fellow
Laura Feeney

Research Fellow

Esther Sanchez de Leon Ley
Esther Sanchez de Leon Ley

Graduate Student

Hexiao Wang
Hexiao Wang

Graduate Student

Chris Wardlaw, PhD
Chris Wardlaw

Research Fellow

Lab Affilations

Lab News & Events

Upcoming event

Setting Boundaries: How Cells Keep Telomeres in Check

This seminar will be conducted by Zoom Webinar.

Open Positions

Career Opportunity

The work in our lab is focused on the DNA damage response (DDR), a network of functions comprising DNA damage signaling, DNA repair, and DNA damage dependent cell cycle regulation. With an overarching interest in chromosome biology, the laboratory employs yeast and mice to undertake genetic, molecular biological, and biochemical analyses of these pathways with a goal of understanding the DDR’s role in tissue homeostasis, development, and tumor suppression. Experience in these research areas is preferred, as are candidates interested in multi-disciplinary approaches

Apply now

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

John Petrini discloses the following relationships and financial interests:

  • Atropos Therapeutics, Inc.
    Ownership / Equity Interests
  • Novus BIologicals
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures